OptiNose, Inc.

Less than two years after being taken private by Gurnet Capital and Novo Holdings, Paratek Pharmaceuticals has agreed to a merger with Optinose that will expand its product portfolio beyond the anti

CG Oncology, Inc. led the latest group of private biotechnology companies that completed $100m-plus venture capital mega-rounds, with a $120m series E financing announced on 15 November, followed clo

OptiNose, Inc. believes it is poised to have the first drug approved by the US Food and Drug Administration for a broad indication for chronic sinusitis (CS). The company reported positive Phase III

Here's your US review and submission news in brief: The Vyondys 53 (golodirsen) saga took a surprising turn last week, as its sponsor Sarepta Therapeutics Inc. scored an approval for the Duchenne mus